<DOC>
	<DOCNO>NCT02568098</DOCNO>
	<brief_summary>Primary Objective - To evaluate safety tolerability co-administered single dose Dihydroartemisinin-Piperaquine ( DHA-PQP ) , Ivermectin ( IVM ) , Primaquine ( PQ ) , Albendazole ( ABZ ) healthy subject . Secondary Objectives - To characterize potential pharmacokinetic interaction DHA-PQP , IVM , PQ , ABZ healthy adult subject . - To characterize pharmacokinetic property PQ ( major metabolite ) , DHA-PQP , IVM , ABZ ( major metabolite ) give alone combination . - To investigate pharmacogenetic polymorphism affect drug level PQ , DHA-PQP , IVM , ABZ metabolites . - To determine mosquito lethal efficacy IVM , PQ , ABZ , DHA-PQP combination Anopheles dirus Anopheles minimus . - To determine IVM concentration venous blood differs capillary blood .</brief_summary>
	<brief_title>Pharmacokinetic Mosquito-Lethal Effects Ivermectin ( IVM ) , Primaquine ( PQ ) , Dihydroartemisinin-Piperaquine ( DHA-PQP ) Albendazole ( ABZ ) Healthy Subjects</brief_title>
	<detailed_description>This open-label , sequential pharmacokinetic study 16 healthy glucose-6-phosphate dehydrogenase ( G6PD ) normal Thai subject . These 16 subject previously participate either study : 1 . Open-Label Study Evaluate Potential Pharmacokinetic Interaction Orally Administered Primaquine ( PQ ) Dihydroartemisinin-Piperaquine ( DHA-PQP ) Healthy Adult Subjects ( TMEC 12-004 ( OxTREC ref . 58-11 ) ) study 2 . Comparison electrocardiographic effect relation Pharmacokinetic profile chloroquine ( CQ ) piperaquine ( PQ ) healthy Thai subject ( TMEC 14-022 ( OxTREC ref . 39-14 ) ) 3. subject previously participate study `` TMEC 12-004 ( OxTREC ref . 58-11 ) '' study `` TMEC 14-022 ( OxTREC ref . 39-14 ) '' . The study team use result DHA-PQP regimen subject mention study compare combination regimen study . This avoid unnecessary exposure Subjects ( TMEC 12-004 ( OxTREC ref . 58-11 ) ) ( TMEC 14-022 ( OxTREC ref . 39-14 ) ) subject . In addition , subject previously test G6PD deficiency screen process mention study result show normal . Therefore , G6PD deficiency test need . A G6PD deficiency test need subject previously participate study subject previously participate study `` TMEC 12-004 ( OxTREC ref . 58-11 ) '' study `` TMEC 14-022 ( OxTREC ref . 39-14 ) '' study . Subjects admit inpatient ward receive single dose 6 regimen ( regimens 1-4 8-9 ) described . Every subject least 6 admission hospital . 1 : IVM ( 400 μg/kg ) via 6 mg tab , w-o** &gt; 4wks ; 2 : IVM ( 400 μg/kg ) +PQ ( 15 mg ) : 2 tab ) , w-o &gt; 4wks ; 3 : IVM ( 400 μg/kg ) +DHA-PQP ( 40mg/320 mg ) : 3 tab ) , w-o &gt; 8wks ; 4 : IVM ( 400 μg/kg ) +DHA-PQP+PQ , w-o &gt; 8wks ; 5* # : PQ ( 15 mg ) : 2 tab , w-o &gt; 2wks ; 6 # : DHA-PQP ( 40mg/320 mg ) : 3 tab , w-o &gt; 8wks ; 7* # : DHA-PQP ( 40mg/320 mg ) : 3 tab +PQ ( 15 mg ) : 2 tab , w-o &gt; 8wks ; 8 : ABZ ( 200 mg ) 2 tab , w-o &gt; 2wks ; 9 : IVM ( 400 μg/kg ) +DHA-PQP ( 40mg/320 mg ) : 3 tabs+PQ ( 15 mg ) : 2 tab +ABZ ( 400 mg ) : 1 tab , w-o &gt; 8wks * The subject TMEC-14-022 ( OxTREC ref . 39-14 ) two additional admission receive two additional regimen PQ , DHA-PQP PQ # Subjects previously participate study `` TMEC 12-004 ( OxTREC ref . 58-11 ) '' study `` TMEC 14-022 ( OxTREC ref . 39-14 ) '' three additional admission receive three additional regimen PQ , DHA-PQP , DHA-PQP PQ . **w-o = washout period</detailed_description>
	<mesh_term>Albendazole</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>1 . Healthy judge responsible physician abnormality identify medical evaluation include medical history physical examination . 2 . Males Females nonsmoker age 18 year 60 year . 3 . Males Females weight 3675 kilogram . 4 . A female eligible enter participate study : nonchildbearing potential include premenopausal female document ( medical report verification ) hysterectomy double oophorectomy postmenopausal define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum follicle stimulate hormone level &gt; 40 milliInternational unit ( mIU/mL ) 6 week postsurgical bilateral oophorectomy without hysterectomy childbearing potential , negative serum pregnancy test screen prior start study drug period , abstain sexual intercourse agree use effective contraceptive method ( e.g. , intrauterine device , hormonal contraceptive drug , tubal ligation female barrier method spermicide ) study completion followup procedures 5 . A male eligible enter participate study : agrees abstain ( use condom ) sexual intercourse female childbearing potential lactating female ; willing use condom/spermicide , study completion followup procedure . 6 . Provide sign dated write informed consent prior study participation . 7 . Normal electrocardiogram ( ECG ) QTc &lt; 450 msec . 8 . Willingness ability comply study protocol duration trial . 1 . Females pregnant , try get pregnant , lactate . 2 . The subject evidence active substance abuse may compromise safety , pharmacokinetics , ability adhere protocol instruction . 3 . A positive prestudy hepatitis B surface antigen , positive hepatitis C antibody , positive human immunodeficiency virus1 ( HIV1 ) antibody result screen . 4 . Subjects personal history cardiac disease , symptomatic asymptomatic arrhythmia , syncopal episode , additional risk factor torsades de point ( heart failure , hypokalemia ) family history sudden cardiac death . 5 . A creatinine clearance ( CLcr ) &lt; 70 mL/min determine CockcroftGault equation : CLcr ( mL/min ) = ( 140 age ) * Wt / ( 72 * Scr ) ( multiply answer 0.85 female ) Where age year , weight ( wt ) kg , serum creatinine ( Scr ) unit mg/dL [ Cockcroft , 1976 ] . 6 . History alcohol substance abuse dependence within 6 month study . 7 . Use prescription ( especially cytochrome P450 3A4 ( CYP3A4 ) inhibitor inducer ) nonprescription drug except paracetamol dose 2 grams/day , include vitamin ( especially vitamin C ) , herbal dietary supplement ( include St. John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 time drug halflife ( whichever longer ) prior first dose study medication completion followup procedure , unless opinion investigator , medication interfere study procedure compromise subject safety ; investigator take advice manufacturer representative necessary . 8 . The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose study medication . 9 . The subject unwilling abstain ingest alcohol within 48 hour prior first dose study medication collection final pharmacokinetic sample regimen . 10 . Subjects donate blood extent participation study would result 300 mL blood donate within 30day period . Plasma donation study acceptable . 11 . Subjects history allergy study drug drug class , history drug allergy , opinion investigator , contraindicate participation trial . In addition , heparin use pharmacokinetic sampling , subject history sensitivity heparin heparininduced thrombocytopenia enrol . 12 . Lack suitability participation study , include limited , unstable medical condition , systemic disease manifest tendency granulocytopenia e.g . rheumatoid arthritis lupus erythematosus opinion investigator would compromise participation trial . 13 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 1.5 upper limit normal ( ULN ) 14 . Subjects history renal disease , hepatic disease , and/or cholecystectomy 15 . Abnormal methaemoglobin level . 16 . History antimalarial drug use include limited mefloquine , chloroquine , primaquine , artesunate , piperaquine pyronaridine treatment within 3 month . 17 . Subject receive quinacrine last 30 day . 18 . The subject unwilling abstain consumption vitamin C 24 hour drug ingestion . 19 . History travel West Central Africa , unless verify subject Loa loa infection . 20 . G6PD deficient detect Beutler 's dye test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Drug combination</keyword>
	<keyword>Ivermectin</keyword>
	<keyword>Primaquine</keyword>
	<keyword>Dihydroartemisinin-Piperaquine</keyword>
	<keyword>Albendazole</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Mosquito-Lethal Effect</keyword>
	<keyword>Healthy adult subject</keyword>
</DOC>